Tanya B Dorff1, Jeff A Longmate2, Sumanta K Pal3, Walter M Stadler4, Mayer N Fishman5, Ulka N Vaishampayan6, Amol Rao1, Jacek K Pinksi1, James S Hu1, David I Quinn7, Primo N Lara8. 1. University of Southern California Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, California. 2. Department of Biostatistics, City of Hope, Duarte, California. 3. Department of Medical Oncology and Experimental Therapeutics, City of Hope, Duarte, California. 4. Hematology/Oncology Section, University of Chicago, Chicago, Illinois. 5. Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 6. Department of Hematology and Oncology, Karmanos Cancer Center, Detroit, Michigan. 7. Department of Medical Oncology, University of Southern California Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, California. 8. University of California Davis Comprehensive Cancer Center, Sacramento, California.
Abstract
BACKGROUND: Targeting the vascular endothelial growth factor (VEGF) pathway has improved outcomes in metastatic renal cell carcinoma (RCC); however, resistance inevitably occurs. CD105 (endoglin) is an angiogenic pathway that is strongly upregulated after VEGF inhibition, potentially contributing to resistance. The authors tested whether TRC105, a monoclonal antibody against endoglin, impacted disease control in patients with previously treated RCC who were receiving bevacizumab. METHODS: Eligible patients with metastatic RCC who had previously received 1 to 4 prior lines of therapy, including VEGF-targeted agents, were randomized 1:1 to receive bevacizumab 10 mg/kg intravenously every 2 weeks (arm A) or the same plus TRC105 10 mg/kg intravenously every 2 weeks (arm B). The primary endpoint was progression-free survival (PFS) at 12 and 24 weeks. Correlative studies included serum transforming growth factor β (TGFβ) and CD105 levels as well as tissue immunostaining for TGFβ receptors. RESULTS: Fifty-nine patients were enrolled (28 on arm A and 31 on arm B), and 1 patient on each arm had a confirmed partial response. The median PFS for bevacizumab alone was 4.6 months compared with 2.8 for bevacizumab plus TRC105 (P = .09). Grade ≥ 3 toxicities occurred in 16 patients (57%) who received bevacizumab compared with 19 (61%) who received bevacizumab plus TRC105 (P = .9). Baseline serum TGFβ levels below the median (<10.6 ng/mL) were associated with longer median PFS (5.6 vs 2.1 months; P = .014). CONCLUSIONS: TRC105 failed to improve PFS when added to bevacizumab. TGFβ warrants further study as a biomarker in RCC. Cancer 2017;123:4566-4573.
BACKGROUND: Targeting the vascular endothelial growth factor (VEGF) pathway has improved outcomes in metastatic renal cell carcinoma (RCC); however, resistance inevitably occurs. CD105 (endoglin) is an angiogenic pathway that is strongly upregulated after VEGF inhibition, potentially contributing to resistance. The authors tested whether TRC105, a monoclonal antibody against endoglin, impacted disease control in patients with previously treated RCC who were receiving bevacizumab. METHODS: Eligible patients with metastatic RCC who had previously received 1 to 4 prior lines of therapy, including VEGF-targeted agents, were randomized 1:1 to receive bevacizumab 10 mg/kg intravenously every 2 weeks (arm A) or the same plus TRC105 10 mg/kg intravenously every 2 weeks (arm B). The primary endpoint was progression-free survival (PFS) at 12 and 24 weeks. Correlative studies included serum transforming growth factor β (TGFβ) and CD105 levels as well as tissue immunostaining for TGFβ receptors. RESULTS: Fifty-nine patients were enrolled (28 on arm A and 31 on arm B), and 1 patient on each arm had a confirmed partial response. The median PFS for bevacizumab alone was 4.6 months compared with 2.8 for bevacizumab plus TRC105 (P = .09). Grade ≥ 3 toxicities occurred in 16 patients (57%) who received bevacizumab compared with 19 (61%) who received bevacizumab plus TRC105 (P = .9). Baseline serum TGFβ levels below the median (<10.6 ng/mL) were associated with longer median PFS (5.6 vs 2.1 months; P = .014). CONCLUSIONS: TRC105 failed to improve PFS when added to bevacizumab. TGFβ warrants further study as a biomarker in RCC. Cancer 2017;123:4566-4573.
Authors: Boris Freidlin; Edward L Korn; Sally Hunsberger; Robert Gray; Scott Saxman; Jo Anne Zujewski Journal: J Clin Oncol Date: 2007-05-20 Impact factor: 44.544
Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: D Y Li; L K Sorensen; B S Brooke; L D Urness; E C Davis; D G Taylor; B B Boak; D P Wendel Journal: Science Date: 1999-05-28 Impact factor: 47.728
Authors: Maximilian Bockhorn; Yoshikazu Tsuzuki; Lei Xu; Andreja Frilling; Christoph E Broelsch; Dai Fukumura Journal: Clin Cancer Res Date: 2003-09-15 Impact factor: 12.531
Authors: James C Yang; Leah Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Seth M Steinberg; Helen X Chen; Steven A Rosenberg Journal: N Engl J Med Date: 2003-07-31 Impact factor: 91.245
Authors: Darren W Davis; Keiji Inoue; Colin P N Dinney; Daniel J Hicklin; James L Abbruzzese; David J McConkey Journal: Cancer Res Date: 2004-07-01 Impact factor: 12.701
Authors: Toni K Choueiri; M Dror Michaelson; Edwin M Posadas; Guru P Sonpavde; David F McDermott; Andrew B Nixon; Yingmiao Liu; Zhenhua Yuan; Ben K Seon; Meghara Walsh; Manoj A Jivani; Bonne J Adams; Charles P Theuer Journal: Oncologist Date: 2018-09-06
Authors: Toni K Choueiri; Yousef Zakharia; Sumanta Pal; Judit Kocsis; Russell Pachynski; Alexandr Poprach; Andrew B Nixon; Yingmiao Liu; Mark Starr; Jing Lyu; Kouros Owzar; Mollie deShazo; Primo Lara; Lajos Geczi; Thai H Ho; Meghara Walsh; Bonne Adams; Liz Robertson; Mohamed Darif; Charles Theuer; Neeraj Agarwal Journal: Oncologist Date: 2021-04-29
Authors: Fabian Hofmann; Eu Chang Hwang; Thomas Bl Lam; Axel Bex; Yuhong Yuan; Lorenzo So Marconi; Börje Ljungberg Journal: Cochrane Database Syst Rev Date: 2020-10-14
Authors: Maria Catalina Gomez-Puerto; Prasanna Vasudevan Iyengar; Amaya García de Vinuesa; Peter Ten Dijke; Gonzalo Sanchez-Duffhues Journal: J Pathol Date: 2018-11-27 Impact factor: 7.996